P. Hall and D. Cameron, Current perspective ??? Trastuzumab, European Journal of Cancer, vol.45, issue.1, pp.12-18, 2009.
DOI : 10.1016/j.ejca.2008.10.013

S. Varchetta, Elements Related to Heterogeneity of Antibody-Dependent Cell Cytotoxicity in Patients Under Trastuzumab Therapy for Primary Operable Breast Cancer Overexpressing Her2, Cancer Research, vol.67, issue.24, pp.11991-11999, 2007.
DOI : 10.1158/0008-5472.CAN-07-2068

R. Clynes, T. Towers, L. Presta, and J. Ravetch, Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets, Nat Med, vol.6, issue.4, pp.443-446, 2000.

R. Gennari, Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2, Clinical Cancer Research, vol.10, issue.17, pp.5650-5655, 2004.
DOI : 10.1158/1078-0432.CCR-04-0225

S. Menard, Apoptosis induction by trastuzumab: research article The Journal of Clinical Investigation http, 2012.

M. Caligiuri, Human natural killer cells, Blood, vol.112, issue.3, pp.461-469, 2008.
DOI : 10.1182/blood-2007-09-077438

URL : https://hal.archives-ouvertes.fr/hal-00431858

K. Tamura, Fc??R2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer, Annals of Oncology, vol.22, issue.6, pp.1302-1307, 2011.
DOI : 10.1093/annonc/mdq585

A. Musolino, ???Positive Metastatic Breast Cancer, Journal of Clinical Oncology, vol.26, issue.11, pp.1789-1796, 2008.
DOI : 10.1200/JCO.2007.14.8957

W. Gluck, Phase I Studies of Interleukin (IL)-2 and Rituximab in B-Cell Non-Hodgkin's Lymphoma: IL-2 Mediated Natural Killer Cell Expansion Correlations with Clinical Response, Clinical Cancer Research, vol.10, issue.7, pp.2253-2264, 2004.
DOI : 10.1158/1078-0432.CCR-1087-3

S. Ansell, Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma, Blood, vol.99, issue.1, pp.67-74, 2002.
DOI : 10.1182/blood.V99.1.67

W. Lin, Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies, Blood, vol.112, issue.3, pp.699-707, 2008.
DOI : 10.1182/blood-2007-11-122465

C. Benz, Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu, Breast Cancer Research and Treatment, vol.51, issue.2, pp.85-95, 1992.
DOI : 10.1007/BF01961241

I. Smith, 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial, The Lancet, vol.369, issue.9555, pp.29-36, 2007.
DOI : 10.1016/S0140-6736(07)60028-2

P. Bedard, E. De-azambuja, and F. Cardoso, Beyond Trastuzumab: Overcoming Resistance to Targeted HER-2 Therapy in Breast Cancer, Current Cancer Drug Targets, vol.9, issue.2, pp.148-162, 2009.
DOI : 10.2174/156800909787581024

N. Spector and K. Blackwell, Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2???Positive Breast Cancer, Journal of Clinical Oncology, vol.27, issue.34, pp.5838-5847, 2009.
DOI : 10.1200/JCO.2009.22.1507

P. Kiewe, Phase I Trial of the Trifunctional Anti-HER2 x Anti-CD3 Antibody Ertumaxomab in Metastatic Breast Cancer, Clinical Cancer Research, vol.12, issue.10, pp.3085-3091, 2006.
DOI : 10.1158/1078-0432.CCR-05-2436

M. Beeram, A phase I study of trastuzumab- MCC-DM1 (T-DM1), a first-in-class HER2 antibodydrug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC), J Clin Oncol, vol.25, p.1042, 2007.

J. Baselga, Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2???Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy, Journal of Clinical Oncology, vol.28, issue.7, pp.1138-1144, 2010.
DOI : 10.1200/JCO.2009.24.2024

R. Newton, Clinical benefit of INCB7839, a potent and selective ADAM inhibitor, in combination with trastuzumab in patients with metastatic HER2+ breast cancer., Journal of Clinical Oncology, vol.28, issue.15_suppl, p.3025, 2010.
DOI : 10.1200/jco.2010.28.15_suppl.3025

L. Salazar, Persistent immunity and survival after immunization with a HER2/neu (HER2) vaccine, J Clin Oncol, vol.27, p.3057, 2009.

I. Melero, S. Hervas-stubbs, G. M. Pardoll, D. Chen, and L. , Immunostimulatory monoclonal antibodies for cancer therapy, Nature Reviews Cancer, vol.10, issue.2, pp.95-106, 2007.
DOI : 10.1038/nrc2051

K. Takeda, Combination Therapy of Established Tumors by Antibodies Targeting Immune Activating and Suppressing Molecules, The Journal of Immunology, vol.184, issue.10, pp.5493-5501, 2010.
DOI : 10.4049/jimmunol.0903033

O. Murillo, Therapeutic Antitumor Efficacy of Anti-CD137 Agonistic Monoclonal Antibody in Mouse Models of Myeloma, Clinical Cancer Research, vol.14, issue.21, pp.6895-6906, 2008.
DOI : 10.1158/1078-0432.CCR-08-0285

R. Wilcox, Cutting Edge: Expression of Functional CD137 Receptor by Dendritic Cells, The Journal of Immunology, vol.168, issue.9, pp.4262-4267, 2002.
DOI : 10.4049/jimmunol.168.9.4262

H. Narazaki, Y. Zhu, L. Luo, G. Zhu, and L. Chen, CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells, Blood, vol.115, issue.10, pp.1941-1948, 2010.
DOI : 10.1182/blood-2008-12-192591

R. Houot, Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion, Blood, vol.114, issue.16, pp.3431-3438, 2009.
DOI : 10.1182/blood-2009-05-223958

T. Baessler, CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells, Blood, vol.115, issue.15, pp.3058-3069, 2010.
DOI : 10.1182/blood-2009-06-227934

I. Melero, J. Johnston, W. Shufford, R. Mittler, and L. Chen, NK1.1 Cells Express 4-1BB (CDw137) Costimulatory Molecule and Are Required for Tumor Immunity Elicited by Anti-4-1BB Monoclonal Antibodies, Cellular Immunology, vol.190, issue.2, pp.167-172, 1998.
DOI : 10.1006/cimm.1998.1396

R. Wilcox, K. Tamada, S. Strome, and L. Chen, Signaling Through NK Cell-Associated CD137 Promotes Both Helper Function for CD8+ Cytolytic T Cells and Responsiveness to IL-2 But Not Cytolytic Activity, The Journal of Immunology, vol.169, issue.8
DOI : 10.4049/jimmunol.169.8.4230

A. Maniar, Human ???? T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement, Blood, vol.116, issue.10, pp.1726-1733, 2010.
DOI : 10.1182/blood-2009-07-234211

W. Gong, Immobilized MHC class I chain-related protein A synergizes with IL-15 and soluble 4-1BB ligand to expand NK cells with high cytotoxicity ex vivo, Cellular and Molecular Immunology, vol.167, issue.6, pp.477-484, 2010.
DOI : 10.1007/s12026-007-0060-9

H. Kohrt, CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies, Blood, vol.117, issue.8, pp.2423-2432, 2011.
DOI : 10.1182/blood-2010-08-301945

URL : https://hal.archives-ouvertes.fr/hal-00743985

M. Cooper, T. Fehniger, and M. Caligiuri, The biology of human natural killer-cell subsets, Trends in Immunology, vol.22, issue.11, pp.633-640, 2001.
DOI : 10.1016/S1471-4906(01)02060-9

J. Bowles and G. Weiner, CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells, Journal of Immunological Methods, vol.304, issue.1-2, pp.88-99, 2005.
DOI : 10.1016/j.jim.2005.06.018

K. Juelke, CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells, Blood, vol.116, issue.8, pp.1299-1307, 2010.
DOI : 10.1182/blood-2009-11-253286

A. Mani, A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab, Breast Cancer Research and Treatment, vol.109, issue.suppl C, pp.83-89, 2009.
DOI : 10.1007/s10549-008-0251-7

N. Acquavella, Toxicity and Activity of a Twice Daily High-dose Bolus Interleukin 2 Regimen in Patients With Metastatic Melanoma and Metastatic Renal Cell Cancer, Journal of Immunotherapy, vol.31, issue.6, pp.569-576, 2008.
DOI : 10.1097/CJI.0b013e318177a4ba

T. Bekaii-saab, A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies, Molecular Cancer Therapeutics, vol.8, issue.11, pp.2983-2991, 2009.
DOI : 10.1158/1535-7163.MCT-09-0820

S. Srivastava, H. Feng, S. Zhang, J. Liang, P. Squiban et al., Enhancing natural killer (NK) cell mediated killing of non-Hodgkin's lymphoma, ASH Annual Meeting Abstracts, vol.114, p.2706, 2009.

D. Jiang and H. Schwarz, Regulation of Granulocyte and Macrophage Populations of Murine Bone Marrow Cells by G-CSF and CD137 Protein, PLoS ONE, vol.30, issue.12, p.15565, 2010.
DOI : 10.1371/journal.pone.0015565.g006

X. Zhang, CD137 Promotes Proliferation and Survival of Human B Cells, The Journal of Immunology, vol.184, issue.2, pp.787-795, 2010.
DOI : 10.4049/jimmunol.0901619

O. Murillo, In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb, European Journal of Immunology, vol.2, issue.9, pp.2424-2436, 2009.
DOI : 10.1002/eji.200838958

R. Sharma, 4-1BB Ligand as an Effective Multifunctional Immunomodulator and Antigen Delivery Vehicle for the Development of Therapeutic Cancer Vaccines, Cancer Research, vol.70, issue.10, pp.3945-3954, 2010.
DOI : 10.1158/0008-5472.CAN-09-4480

F. Bellati, C. Napoletano, I. Ruscito, M. Liberati, P. Panici et al., Cellular Adaptive Immune System Plays a Crucial Role in Trastuzumab Clinical Efficacy, Journal of Clinical Oncology, vol.28, issue.21, pp.369-370, 2010.
DOI : 10.1200/JCO.2010.28.6922

J. Stagg, Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy, Proceedings of the National Academy of Sciences, vol.108, issue.17, pp.7142-7147, 2011.
DOI : 10.1073/pnas.1016569108

F. Li and J. Ravetch, Inhibitory Fc?? Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies, Science, vol.333, issue.6045, pp.1030-1034, 2011.
DOI : 10.1126/science.1206954

J. Dubrot, Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ, Cancer Immunology, Immunotherapy, vol.25, issue.8, pp.1223-1233, 2010.
DOI : 10.1007/s00262-010-0846-9

M. Sznol, Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA), Journal of Clinical Oncology, vol.26, issue.15_suppl, p.3007, 1920.
DOI : 10.1200/jco.2008.26.15_suppl.3007

S. Mohsin, Neoadjuvant Trastuzumab Induces Apoptosis in Primary Breast Cancers, Journal of Clinical Oncology, vol.23, issue.11, pp.2460-2468, 2005.
DOI : 10.1200/JCO.2005.00.661

A. Belkhiri, Expression of t-DARPP Mediates Trastuzumab Resistance in Breast Cancer Cells, Clinical Cancer Research, vol.14, issue.14, pp.4564-4571, 2008.
DOI : 10.1158/1078-0432.CCR-08-0121

C. Yamauchi, E-cadherin expression on human carcinoma cell affects trastuzumab-mediated antibody-dependent cellular cytotoxicity through killer cell lectin-like receptor G1 on natural killer cells, International Journal of Cancer, vol.182, issue.9
DOI : 10.1002/ijc.25803

R. Wilcox, Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors, Journal of Clinical Investigation, vol.109, issue.5
DOI : 10.1172/JCI0214184

G. Kim, V. Donnenberg, A. Donnenberg, W. Gooding, and T. Whiteside, A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: Comparisons to a 4??h 51Cr-release assay, Journal of Immunological Methods, vol.325, issue.1-2, pp.51-66, 2007.
DOI : 10.1016/j.jim.2007.05.013

N. Kotecha, Single-Cell Profiling Identifies Aberrant STAT5 Activation in Myeloid Malignancies with Specific Clinical and Biologic Correlates, Cancer Cell, vol.14, issue.4, pp.335-343, 2008.
DOI : 10.1016/j.ccr.2008.08.014